163 related articles for article (PubMed ID: 35649961)
1. Luminescent Assay for the Screening of SARS-CoV-2 M
Sondag D; Merx J; Rossing E; Boltje TJ; Löwik DWPM; Nelissen FHT; van Geffen M; van 't Veer C; van Heerde WL; Rutjes FPJT
Chembiochem; 2022 Aug; 23(15):e202200190. PubMed ID: 35649961
[TBL] [Abstract][Full Text] [Related]
2. Easy access to α-ketoamides as SARS-CoV-2 and MERS M
Pelliccia S; Cerchia C; Esposito F; Cannalire R; Corona A; Costanzi E; Kuzikov M; Gribbon P; Zaliani A; Brindisi M; Storici P; Tramontano E; Summa V
Eur J Med Chem; 2022 Dec; 244():114853. PubMed ID: 36332546
[TBL] [Abstract][Full Text] [Related]
3. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.
Deodato D; Asad N; Dore TM
Bioorg Med Chem Lett; 2022 Sep; 72():128867. PubMed ID: 35760254
[TBL] [Abstract][Full Text] [Related]
5. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
6. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
Martorana A; Gentile C; Lauria A
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
[TBL] [Abstract][Full Text] [Related]
7. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
9. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
Göhl M; Zhang L; El Kilani H; Sun X; Zhang K; Brönstrup M; Hilgenfeld R
Molecules; 2022 Jul; 27(13):. PubMed ID: 35807537
[TBL] [Abstract][Full Text] [Related]
10. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.
La Monica G; Bono A; Lauria A; Martorana A
J Med Chem; 2022 Oct; 65(19):12500-12534. PubMed ID: 36169610
[TBL] [Abstract][Full Text] [Related]
11. Primer for Designing Main Protease (M
Thakur A; Sharma G; Badavath VN; Jayaprakash V; Merz KM; Blum G; Acevedo O
J Phys Chem Lett; 2022 Jun; 13(25):5776-5786. PubMed ID: 35726889
[TBL] [Abstract][Full Text] [Related]
12. Molecular interactions and inhibition of the SARS-CoV-2 main protease by a thiadiazolidinone derivative.
Andrzejczyk J; Jovic K; Brown LM; Pascetta VG; Varga K; Vashisth H
Proteins; 2022 Nov; 90(11):1896-1907. PubMed ID: 35567429
[TBL] [Abstract][Full Text] [Related]
13. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
[TBL] [Abstract][Full Text] [Related]
14. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
[TBL] [Abstract][Full Text] [Related]
15. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
[TBL] [Abstract][Full Text] [Related]
16. Targeting allosteric pockets of SARS-CoV-2 main protease M
Bhat ZA; Chitara D; Iqbal J; Sanjeev BS; Madhumalar A
J Biomol Struct Dyn; 2022 Sep; 40(14):6603-6618. PubMed ID: 33645457
[TBL] [Abstract][Full Text] [Related]
17. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
18. Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity.
Liu C; Puopolo T; Li H; Cai A; Seeram NP; Ma H
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144858
[TBL] [Abstract][Full Text] [Related]
19. Structure of M
Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H
Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481
[TBL] [Abstract][Full Text] [Related]
20. Dual Inhibitors of Main Protease (M
Mondal S; Chen Y; Lockbaum GJ; Sen S; Chaudhuri S; Reyes AC; Lee JM; Kaur AN; Sultana N; Cameron MD; Shaffer SA; Schiffer CA; Fitzgerald KA; Thompson PR
J Am Chem Soc; 2022 Nov; 144(46):21035-21045. PubMed ID: 36356199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
